PMID- 36623835
OWN - NLM
STAT- MEDLINE
DCOM- 20230417
LR  - 20230417
IS  - 1439-3646 (Electronic)
IS  - 0947-7349 (Linking)
VI  - 131
IP  - 4
DP  - 2023 Apr
TI  - Fasting Plasma Glucose Increase and Neutrophil-to-Lymphocyte Ratio as Risk 
      Predictors of Clinical Outcome of COVID-19 Pneumonia in Type 2 Diabetes Mellitus.
PG  - 194-197
LID - 10.1055/a-2009-6937 [doi]
AB  - AIM OF THE STUDY: To evaluate fasting plasma glucose (FPG) increase and 
      neutrophil-to-lymphocyte ratio (NLR) as risk predictors of severe clinical 
      outcome of COVID-19 pneumonia in type 2 diabetes mellitus (T2DM) hospitalised 
      patients. PATIENTS AND METHODS: Type 2 diabetes mellitus (T2DM) patients 
      hospitalised between March 2020 and February 2021 were studied retrospectively. 
      The NLR ratio at admission and FPG increase (day 7, day with maximal FPG) were 
      evaluated in association with the clinical progression of SARS-CoV-2 infection. 
      RESULTS: Three hundred patients (165 men, 135 women) were included in the study. 
      The mean age was 67.17+/-8.65 years. Severe COVID-19 pneumonia was diagnosed in 170 
      patients (56.7%). Fifty-four patients (18%) were intubated and 49 (16.3%) died. 
      Greater increase in FPG (79.5 vs. 44.5 mg/dL for day 1-7, p<0.001; and 113.5 vs. 
      75 mg/dL for day 1-day with maximum glucose value, p<0.001) and higher NLR at 
      admission (10.65 vs. 6.85) were seen in patients with need of high-flow oxygen 
      compared to those without need, and they were associated with a higher 
      probability of intubation and death. CONCLUSION: FPG increase and NLR could be 
      significant risk predictors of severe COVID-19 pneumonia in T2DM hospitalised 
      patients.
CI  - Thieme. All rights reserved.
FAU - Petrakis, Vasilios
AU  - Petrakis V
AD  - Department of Infectious Diseases, Second Department of Internal Medicine, 
      Democritus University of Thrace, University Hospital of Alexandroupolis, Greece.
FAU - Panagopoulos, Periklis
AU  - Panagopoulos P
AD  - Department of Infectious Diseases, Second Department of Internal Medicine, 
      Democritus University of Thrace, University Hospital of Alexandroupolis, Greece.
FAU - Trypsianis, Grigorios
AU  - Trypsianis G
AD  - Department of Medical Statistics, Medical School, Democritus University of 
      Thrace.
FAU - Papazoglou, Dimitrios
AU  - Papazoglou D
AD  - Department of Infectious Diseases, Second Department of Internal Medicine, 
      Democritus University of Thrace, University Hospital of Alexandroupolis, Greece.
FAU - Papanas, Nikolaos
AU  - Papanas N
AD  - Diabetes Centre, Second Department of Internal Medicine, Democritus University of 
      Thrace, University Hospital of Alexandroupolis, Greece.
LA  - eng
PT  - Journal Article
DEP - 20230109
PL  - Germany
TA  - Exp Clin Endocrinol Diabetes
JT  - Experimental and clinical endocrinology & diabetes : official journal, German 
      Society of Endocrinology [and] German Diabetes Association
JID - 9505926
RN  - 0 (Blood Glucose)
SB  - IM
MH  - Male
MH  - Humans
MH  - Female
MH  - Middle Aged
MH  - Aged
MH  - *COVID-19/complications
MH  - *Diabetes Mellitus, Type 2/complications
MH  - Blood Glucose
MH  - Retrospective Studies
MH  - Neutrophils
MH  - SARS-CoV-2
MH  - Fasting
MH  - Lymphocytes
COIS- NP has been an advisory board member of TrigoCare International, Abbott, 
      AstraZeneca, Elpen, MSD, Novartis, Novo Nordisk, Sanofi-Aventis and Takeda; has 
      participated in sponsored studies by Eli Lilly, MSD, Novo Nordisk, Novartis and 
      Sanofi-Aventis; received honoraria as a speaker for AstraZeneca, Boehringer 
      Ingelheim, Eli Lilly, Elpen, Galenica, MSD, Mylan, Novartis, Novo Nordisk, 
      Pfizer, Sanofi-Aventis, Takeda and Vianex; and attended conferences sponsored by 
      TrigoCare International, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novartis, 
      Novo Nordisk, Pfizer and Sanofi-Aventis. PP has been an advisory board member of 
      GS, MSD, JANSSEN and received honoraria as a speaker for GS, JANSSEN, MSD.
EDAT- 2023/01/10 06:00
MHDA- 2023/04/17 06:41
CRDT- 2023/01/09 20:02
PHST- 2023/04/17 06:41 [medline]
PHST- 2023/01/10 06:00 [pubmed]
PHST- 2023/01/09 20:02 [entrez]
AID - 10.1055/a-2009-6937 [doi]
PST - ppublish
SO  - Exp Clin Endocrinol Diabetes. 2023 Apr;131(4):194-197. doi: 10.1055/a-2009-6937. 
      Epub 2023 Jan 9.